Receptor changes in metachronous breast tumors—our experience of 10 years

• Published in: The American journal of surgery 2012-03, Vol.203 (3), p.405-409
• Main Authors: Bhullar, Jasneet Singh, M.D., M.S, Unawane, Amruta, M.D, Subhas, Gokulakkrishna, M.D., M.R.C.S, Poonawala, Husein, M.D, Dubay, Linda, M.D, Ferguson, Lorenzo, M.D, Goriel, Yousif, M.D, Jacobs, Michael J., M.D, Kolachalam, Ramachandra B., M.D, Silapaswan, Sumet, M.D, Mittal, Vijay K., M.D., F.A.C.S
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Aged, 80 and over; Bilateral breast cancer; Biological and medical sciences; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cancer; Cancer therapies; Charts; Chemotherapy; Combined Modality Therapy; Endocrine therapy; ErbB-2 protein; Estrogen; Estrogen receptors; Estrogens; Female; General aspects; Gynecology. Andrology. Obstetrics; Health risk assessment; Health risks; Humans; Lymphatic Metastasis; Mammary gland diseases; Mastectomy; Medical prognosis; Medical sciences; Metachronous breast cancer; Metastasis; Middle Aged; Neoplasms, Second Primary - metabolism; Neoplasms, Second Primary - pathology; Neoplasms, Second Primary - therapy; Patients; Progesterone; Progesterone receptors; Receptor, ErbB-2 - metabolism; Receptors; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Retrospective Studies; Studies; Surgery; Synchronous breast cancer; Tumors
• ISSN: 0002-9610; 1879-1883
• DOI: 10.1016/j.amjsurg.2011.09.010

Abstract Introduction Patients with primary breast cancer (PBC) are at 2 to 6 times higher risk for developing synchronous and metachronous breast cancer (MBC). The pathology and behavior of MBC still remains unclear. Methods We reviewed the charts of 108 women with MBC at our hospital over the past 10 years. Profile patterns of the estrogen receptor (ER), the progesterone receptor (PR), and Her2/neu receptors were explored. Results Of 33 patients with ER+ /PR+ in the primary tumor, 23 (70%) retained the status in MBC. Forty-five (92%) of 49 patients with ER− /PR− in the primary tumor remained the same in MBC. Most Her2− tumors (22/31, 71%) remained negative, but 50% (8/16) of Her2+ tumors became negative. Conclusions Most MBC retained the ER/PR expression patterns irrespective of the treatment for the primary tumor, thus suggesting a common origin. Because MBCs tend to be triple negative and thus more aggressive, early detection and close surveillance techniques must be devised.